For cell therapy research and clinical applications, Sino Biological is devoted to manufacturing high-quality reagents. By applying a quality management system that sticks to GMP standards ...

The EU-based GMP manufacturer has large-scale commercial production capabilities, facilitating reliable and compliant manufacturing for Polyrizon's clinical trial needs. Polyrizon develops ...

(the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today it has commenced preliminary work related to the ...

announces today it has commenced preliminary work related to the Good Manufacturing Practice (GMP) manufacturing process for its PL-14 allergy blocker in preparation for its planned 2025 clinical ...

With a strong emphasis on product development and its internal clinical GMP manufacturing infrastructure, Rise is focused on developing immunological-based biological medicines using a unique and ...

consistent clinical manufacturing. Streamlined Regulatory Pathway: The GMP PSXi013 iPSC line will be supported by a Drug Master File (DMF) submission to the US FDA to simplify the Investigational ...

Polyrizon announced preliminary work for GMP manufacturing of its PL-14 allergy blocker in preparation for a 2025 clinical trial. Who is Eurofins CDMO Amatsiaquitaine S.A.S.? Eurofins CDMO ...

VANCOUVER, BC, Dec. 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that in anticipation of restarting ...

She facilitated the company’s commercial activities by negotiating contracts for CGT process development and GMP manufacturing across all clinical stages. Before joining Lonza in 2019 ...

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...

VANCOUVER, BC, Dec. 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that ...